Spots Global Cancer Trial Database for Assessment of the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Assessment of the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell Carcinoma
Official Title: A Single-arm Open-label Phase II Trial to Assess the Efficacy and Safety of Pembrolizumab for Unresectable Advanced or Recurrent Ovarian Squamous Cell Carcinoma
Study ID: NCT05737199
Conditions
Interventions
Study Description
Brief Summary: This is a phase II, non-randomized, open-label, single-arm, multicenter study to evaluate the efficacy and safety of MK-3475 in patients with ovarian squamous cell carcinoma.
Detailed Description: This study includes female patients 18 years of age or older with advanced or recurrent unresectable squamous cell carcinoma of the ovary. Pembrolizumab will be given for a maximum of 2 years i.e. a total of 35 cycles of pembrolizumab with the q3 week dosing.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Niigata University Medical & Dental Hosptal, Niigata, , Japan
Contact Details
Name: Kosuke Yoshihara, Professor
Affiliation: Niigata University Medical & Dental Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
